Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.

Lesokhin A, LeBlanc R, Dimopoulos MA, Capra M, Carlo-Stella C, Karlin L, Castilloux JF, Forsberg P, Parmar G, Tosikyan A, Pour L, Ribrag V, Ribolla R, Abdallah AO, Le Roux N, Dong L, van de Velde H, Mayrargue L, Lépine L, Macé S, Moreau P

Open source

DOI: 10.1002/cam4.5753
Published: 2023 May
Container: Cancer medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cam4.5753,
  title = {Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.},
  author = {Lesokhin A and LeBlanc R and Dimopoulos MA and Capra M and Carlo-Stella C and Karlin L and Castilloux JF and Forsberg P and Parmar G and Tosikyan A and Pour L and Ribrag V and Ribolla R and Abdallah AO and Le Roux N and Dong L and van de Velde H and Mayrargue L and Lépine L and Macé S and Moreau P},
  year = {2023},
  journal = {Cancer medicine},
  doi = {10.1002/cam4.5753},
  url = {https://doi.org/10.1002/cam4.5753}
}

RIS

TY  - JOUR
TI  - Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.
AU  - Lesokhin A
AU  - LeBlanc R
AU  - Dimopoulos MA
AU  - Capra M
AU  - Carlo-Stella C
AU  - Karlin L
AU  - Castilloux JF
AU  - Forsberg P
AU  - Parmar G
AU  - Tosikyan A
AU  - Pour L
AU  - Ribrag V
AU  - Ribolla R
AU  - Abdallah AO
AU  - Le Roux N
AU  - Dong L
AU  - van de Velde H
AU  - Mayrargue L
AU  - Lépine L
AU  - Macé S
AU  - Moreau P
PY  - 2023
JO  - Cancer medicine
DO  - 10.1002/cam4.5753
UR  - https://doi.org/10.1002/cam4.5753
ER  -

APA

A, L., R, L., MA, D., M, C., C, C., L, K., JF, C., P, F., G, P., A, T., L, P., V, R., R, R., AO, A., N, L. R., L, D., H, V. D. V., L, M., L, L., S, M., & P, M. (2023). Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.. Cancer medicine. https://doi.org/10.1002/cam4.5753

Source records

pubmed · retrieved 2026-09-26T08:27:50.942Z